Summary & Overview
HCPCS P9031: Platelets, Leukocytes Reduced, Each Unit
HCPCS Level II code P9031 designates a single unit of platelets that has been leukocyte-reduced. This blood component coding is important nationally because leukoreduced platelets are widely used to reduce transfusion-related complications and to meet clinical and payer expectations for safer blood products. The code supports billing for the specific product type and informs clinical workflows, inventory tracking, and payment processes across acute care and outpatient settings.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical context, typical sites of service, and the role leukoreduced platelets play in transfusion medicine. The publication also outlines benchmarks and payer coverage patterns, relevant policy considerations affecting reimbursement and billing practices, and operational implications for hospitals, transfusion services, and outpatient infusion centers.
This summary provides actionable clarity on coding for leukocyte-reduced platelet units, helping billing professionals, clinicians, and administrators understand classification, expected use cases, and where to look for payer-specific rules and documentation requirements. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code P9031 describes platelets, leukocytes reduced, each unit. This code represents a blood product unit in which leukocytes (white blood cells) have been reduced, typically through filtration or other leukoreduction processes, to lower the risk of febrile nonhemolytic transfusion reactions and reduce certain alloimmunization and infectious risks.
Service Type: Blood product transfusion / blood component supply
Typical Site of Service: Hospital inpatient, hospital outpatient infusion center, ambulatory surgical center, and transfusion service laboratories
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with chemotherapy-induced thrombocytopenia for treatment of metastatic solid tumor requires transfusion of platelets that have been leukocyte-reduced to minimize febrile nonhemolytic transfusion reactions and alloimmunization. The patient presents to the hospital transfusion service or outpatient oncology infusion center. Pretransfusion testing includes verification of indication, review of recent platelet counts and bleeding status, type and screen, and informed consent. The blood bank issues units labeled as P9031 (Platelets, leukocytes reduced, each unit). During administration, nursing monitors vital signs and for transfusion reactions; documentation includes unit numbers, lot numbers, start/stop times, and patient response. Post-transfusion platelet count and clinical reassessment guide further transfusion decisions. Typical sites of service are inpatient hospital units, outpatient hospital-based infusion centers, and ambulatory oncology clinics with transfusion capabilities.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct Procedural Service | When reporting a separately identifiable service that is distinct from other services on the same day (use cautiously; rarely applied to blood product supply). |